To the Editor Walsh et al1 present data on 1007 Jewish women with breast cancer who were sequenced for 23 candidate genes. There were 111 carriers of a BRCA1 or BRCA2 mutation identified, 29 carriers of a CHEK2 mutation, 1 carrier of an NBN mutation, and 1 carrier of a BRIP1 mutation. The authors use these data to support their position that use of a 23-gene panel is preferable to testing for BRCA1 and BRCA2 alone. We look at the same data and conclude that testing should be limited to BRCA1 and BRCA2.
Narod S, Sopik V, Cybulski C. Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2. JAMA Oncol. 2018;4(7):1012. doi:10.1001/jamaoncol.2018.0595
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.